TORONTO, Feb. 07, 2020 (GLOBE NEWSWIRE) -- On February 3, 2020, the Quebec Superior Court granted BlackRock Asset Management Canada Limited, iShares Trust, iShares, Inc. and BlackRock Institutional Trust Company, N.A. (collectively, the “Plaintiffs”) authorization to pursue a secondary market claim under Title VIII, Chapter II, Division II of the Quebec Securities Act (“QSA”) in relation to Valeant Pharmaceuticals International, Inc. (n/k/a Bausch Health Companies Inc.) (“Valeant”) shares purchased from February 28, 2013 to August 10, 2016.
Authorization under the QSA has been granted against Valeant and certain of its former officers and directors—namely, J. Michael Pearson, Howard B. Schiller, Robert L. Rosiello, Robert A. Ingram, Ronald H. Farmer, Theo Melas-Kyriazi, G. Mason Morfit, Dr. Laurence Paul, Robert N. Power, Norma A. Provencio, Lloyd M. Segal, Katharine B. Stevenson, Fred Hassan, Colleen Goggins, and Jeffrey W. Ubben (collectively, the “Defendants”). The Plaintiffs’ claim is based on allegations that Valeant’s filings with securities regulators in Canada and the United States contained materially false or misleading statements regarding Valeant’s business practices, financial results, and other material facts. The Defendants dispute the Plaintiffs’ claim.
The Plaintiffs are represented by Belleau Lapointe, LLP and Lieff Cabraser Heimann & Bernstein, LLP.
About BlackRock
BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, our clients turn to us for the solutions they need when planning for their most important goals. As of December 31, 2019, the firm managed approximately US$7.43 trillion in assets on behalf of investors worldwide. For additional information on BlackRock, please visit www.blackrock.com/ca | Twitter: @BlackRockCA | LinkedIn: www.linkedin.com/company/blackrock.
Contact for Media:
Maeve Hannigan
T – 416-643-4058
Email: Maeve.Hannigan@blackrock.com